Antibody Drug Conjugates: Clinical Trial Tracker

Description: Antibody drug conjugates (ADCs) are a new class of therapeutic agents, which are gaining increasing attention from both large and small pharmaceutical companies. Generally addressed as the marriage of an antibody with a toxic drug / chemotherapy drug, these conjugates are believed to be more efficient and effective in the treatment of a disease.

The ADC market is still in its infancy. The recent launch of Roche's much awaited Kadcyla (T-DM1) has provided a positive outlook to the future of the market. The pipeline is rich, though not many molecules are in the pivotal trial stage yet. It will be a few years before the market picks up pace with the launch of several pipeline drugs. Majority of the ADCs currently under development are for oncological indications, driven by the availability of monoclonal antibodies targeting various types of cancer.

The primary objective of this report is to capture details on the various clinical and preclinical trials which are currently underway in the field of Antibody Drug Conjugates. A number of such trials have been identified which are taking place for a variety of indications across multiple geographies.

For each specific trial, the following information is provided:

- Trial Objective
- Manufacturer / Licensee
- Technology Provider
- Antibody
- Cytotoxin
- Linker
- Type of Cancer
- Indication
- Sponsor / Collaborator
- Trial Phase
- Trial Status
- Start Date
- End Date
- Enrolment
- Age Group
- Inclusion Criteria
- Exclusion Criteria
- Study Design
- Primary Endpoint
- Secondary Endpoint
- Treatment Arms
- Route of Administration
- Location(s)
- Trial Results (if known)

The above information has also been presented in the form a dashboard to provide a high level quick overview of the ongoing activity in this space.

Also Included:

- Detailed forecasts of the ADC market over the course of next ten years. Owing to the niche nature of this market, three scenarios have been presented to add robustness to the market forecast. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.

- Industry SWOT analysis summarising the challenges as well as opportunities in the market for different stakeholders.

- A case study on CMOs, one of the key players in emergence of the ADC market
Research Methodology

Most of the data presented in this report has been gathered by secondary research. Also conducted are interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful to draw out opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Other analysts' opinion reports

While the focus has been on forecasting the market over the coming ten years, the report also provides an independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Contents:

1. Introduction and Pipeline Details
   Section 1. Market Overview
   Section 2. Dashboard: Pipeline Analysis
   Section 3. Molecules in Clinical Development: Trial Details
   Section 4. Molecules in Preclinical Development: Trial Details

2. Market Forecast, 2013 - 2023
   Section 5. Market Forecast: Assumptions
   Section 6. Market Forecast: Details
   Section 7. Comparative Forecast Scenarios

3. Industry Analysis
   Section 8. Industry SWOT Analysis
   Section 9. Case Study: Contract Manufacturing in ADCs

List of Figures

Pipeline Details
Figure 1: ADCs in Clinical Development: Distribution by Companies
Figure 2: ADCs in Clinical Development: Distribution by Highest Phase of Development
Figure 3: ADCs in Clinical Development: Distribution by Type of Antibody
Figure 4: ADCs in Clinical Development: Distribution by Type of Cytotoxin
Figure 5: ADC Clinical Trials: Distribution by Phase of Development
Figure 6: ADC Clinical Trials: Distribution by Trial Status
Figure 7: ADC Clinical Trials: Distribution by Sponsor Type
Figure 8: ADC Clinical Trials: Distribution by Cancer Type
Figure 9: ADCs in Preclinical Development: Distribution by Companies

Market Forecast
Figure 10: ADC Market Forecast, Base Scenario (USD MM)
Figure 11: ADC Market Forecast, Scenario Comparison (USD MM)

List of Tables
Pipeline Details

Table 1: Molecules in Clinical Development: Pipeline Details
Table 2: Molecules in Preclinical Development: Pipeline Details

Market Forecast

Table 3: Expected Launch Year of ADCs in Clinical Development

Industry Analysis

Table 4: SWOT Analysis
Table 5: Contract Manufacturers and Their Capabilities

Ordering:  
Order Online - http://www.researchandmarkets.com/reports/2692384/  
Order by Fax - using the form below  
Order by Post - print the order form below and send to

Research and Markets,  
Guinness Centre,  
Taylors Lane,  
Dublin 8,  
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Antibody Drug Conjugates: Clinical Trial Tracker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/2692384/">http://www.researchandmarkets.com/reports/2692384/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SCD27F5S</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic - Single User:</td>
<td>USD 799</td>
</tr>
<tr>
<td>Electronic - Site License:</td>
<td>USD 1599</td>
</tr>
<tr>
<td>Electronic - Enterprisewide:</td>
<td>USD 2399</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ________________________ Last Name: ________________________
Email Address: * ________________________
Job Title: ________________________
Organisation: ________________________
Address: ________________________
City: ________________________
Postal / Zip Code: ________________________
Country: ________________________
Phone Number: ________________________
Fax Number: ________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World